COMPANY
Boothwyn Pharmacy LLC
Boothwyn Pharmacy LLC: warning letter recipient, recalling firm for Semaglutide, Tirzepatide, as stated by public registers.
Also written as: Boothwyn Pharmacy, LLC.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | Compounding Pharmacy/Adulterated Drug Products, 2026-01-16 Regulator FDA warning letters |
|---|---|
| Tirzepatide | Compounding Pharmacy/Adulterated Drug Products, 2026-01-16 Regulator FDA warning letters |
RECALLING FIRM
Recalled a product naming the peptide (FDA enforcement report).
| Semaglutide | Class II recall, Ongoing, 2025-09-10 Regulator openFDA |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.